News

Article

Opus Enters Collaboration with Resilience for AAV-Based Gene Therapy Development and Manufacturing

Opus enters a strategic collaboration with Resilience for AAV-based gene therapy development and manufacturing for inherited retinal diseases.

Opus Genetics, a gene therapy company focused on inherited retinal diseases, announced on April 11, 2022 that it is entering a manufacturing services agreement with Resilience, a technology-focused biomanufacturing company, to support the development and manufacturing of Opus’ pipeline.

Resilience will provide process and analytical development, quality control testing, and good manufacturing practice manufacturing services for Opus’ adeno-associated viral (AAV) vector-based gene therapies for inherited retinal diseases for use in both preclinical studies and future clinical trials in the United States. This work will take place at Resilience’s facilities in Waltham, Mass., and Research Triangle Park, NC.

“Resilience embraces our innovative model to create a clinical manufacturing infrastructure that’s scaled to address rare inherited retinal diseases, and we are pleased to enter into this strategic collaboration,” said Ben Yerxa, PhD, CEO of the Foundation Fighting Blindness and the Retinal Degeneration Fund, and acting CEO of Opus, in a press release. “Leveraging Resilience’s expertise puts Opus in the best position to efficiently advance our AAV-based gene therapies into the clinic and toward the patients who need them.”

“Helping Opus advance their gene therapies for inherited retinal diseases to the clinic will hopefully lead to new treatments for underserved patients,” said Rahul Singhvi, ScD, CEO of Resilience, in the release. “We’re excited to partner with Opus on process development and manufacturing at this pivotal time for the company.”

Source: Opus

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content